Forte Biosciences, Inc. is a biopharmaceutical company that is advancing through preclinical development its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications. Forte’s lead product, FB-102, is a proprietary molecule with potential as a first-in-class biotherapeutic for the treatment of autoimmune diseases. Forte’s initial focus will be on Alopecia Areata, Graft-versus-Host Disease (GvHD)/Transplant Rejection and Vitiligo, large indications with unmet needs.